Quels sont les principaux facteurs de risque pour les troubles des cotransporteurs ?
Les antécédents familiaux, les maladies rénales et une alimentation déséquilibrée sont des facteurs de risque.
Facteurs de risqueAntécédents familiauxMaladies rénales
#2
L'âge influence-t-il le risque de troubles ?
Oui, le risque augmente avec l'âge, surtout chez les personnes âgées.
ÂgeRisquePersonnes âgées
#3
Les maladies métaboliques sont-elles un facteur de risque ?
Oui, des maladies comme le diabète peuvent augmenter le risque de dysfonction des cotransporteurs.
Maladies métaboliquesDiabèteRisque
#4
Le mode de vie influence-t-il le risque ?
Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.
Mode de vieSédentaritéAlimentation
#5
Les médicaments peuvent-ils affecter le risque ?
Oui, certains médicaments peuvent interférer avec la fonction des cotransporteurs et augmenter le risque.
MédicamentsInterférenceRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cotransporteurs sodium-phosphate de type IIc : Questions médicales les plus fréquentes",
"headline": "Cotransporteurs sodium-phosphate de type IIc : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cotransporteurs sodium-phosphate de type IIc : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-26",
"dateModified": "2026-07-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cotransporteurs sodium-phosphate de type IIc"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cotransporteurs sodium-phosphate de type II",
"url": "https://questionsmedicales.fr/mesh/D050610",
"about": {
"@type": "MedicalCondition",
"name": "Cotransporteurs sodium-phosphate de type II",
"code": {
"@type": "MedicalCode",
"code": "D050610",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.585.937.829"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cotransporteurs sodium-phosphate de type IIc",
"alternateName": "Sodium-Phosphate Cotransporter Proteins, Type IIc",
"code": {
"@type": "MedicalCode",
"code": "D050615",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hiroko Segawa",
"url": "https://questionsmedicales.fr/author/Hiroko%20Segawa",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. segawa@tokushima-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Ken-Ichi Miyamoto",
"url": "https://questionsmedicales.fr/author/Ken-Ichi%20Miyamoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. kmiyamoto@tokushima-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Deborah J Wexler",
"url": "https://questionsmedicales.fr/author/Deborah%20J%20Wexler",
"affiliation": {
"@type": "Organization",
"name": "Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Elisabetta Patorno",
"url": "https://questionsmedicales.fr/author/Elisabetta%20Patorno",
"affiliation": {
"@type": "Organization",
"name": "Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."
}
},
{
"@type": "Person",
"name": "Toru Fujii",
"url": "https://questionsmedicales.fr/author/Toru%20Fujii",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.",
"datePublished": "2024-01-02",
"url": "https://questionsmedicales.fr/article/38170522",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2023.50050"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease.",
"datePublished": "2024-03-15",
"url": "https://questionsmedicales.fr/article/38586086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.62347/UGTW5471"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus.",
"datePublished": "2024-08-09",
"url": "https://questionsmedicales.fr/article/39128564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diabres.2024.111818"
}
},
{
"@type": "ScholarlyArticle",
"name": "The interplay between sodium/glucose cotransporter type 2 and mitochondrial ionic environment.",
"datePublished": "2024-04-08",
"url": "https://questionsmedicales.fr/article/38599300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.mito.2024.101878"
}
},
{
"@type": "ScholarlyArticle",
"name": "The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.",
"datePublished": "2024-03-12",
"url": "https://questionsmedicales.fr/article/38472344",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41584-024-01092-x"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de transport membranaire",
"item": "https://questionsmedicales.fr/mesh/D026901"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines transporteurs de solutés",
"item": "https://questionsmedicales.fr/mesh/D000070590"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cotransporteurs sodium-phosphate de type II",
"item": "https://questionsmedicales.fr/mesh/D050610"
},
{
"@type": "ListItem",
"position": 8,
"name": "Cotransporteurs sodium-phosphate de type IIc",
"item": "https://questionsmedicales.fr/mesh/D050615"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cotransporteurs sodium-phosphate de type IIc - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Comment diagnostiquer une dysfonction des cotransporteurs ?\nQuels examens sont utilisés pour évaluer les cotransporteurs ?\nQuels symptômes indiquent un problème de cotransporteurs ?\nPeut-on détecter des anomalies par imagerie ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Quels sont les symptômes d'une carence en phosphate ?\nComment se manifeste un excès de phosphate ?\nLes troubles osseux sont-ils liés aux cotransporteurs ?\nQuels signes cliniques sont associés aux cotransporteurs ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Comment prévenir les troubles liés aux cotransporteurs ?\nLes antécédents familiaux influencent-ils la prévention ?\nL'exercice physique a-t-il un impact sur la santé des cotransporteurs ?\nDes suppléments préventifs sont-ils recommandés ?\nComment l'hydratation influence-t-elle la santé des cotransporteurs ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Quels traitements sont disponibles pour les troubles des cotransporteurs ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nLes traitements sont-ils différents pour les enfants ?\nDes thérapies alternatives sont-elles efficaces ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Quelles complications peuvent survenir avec une dysfonction des cotransporteurs ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles plus fréquentes chez certains groupes ?\nQuelles mesures peuvent réduire les complications ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cotransporteurs sodium-phosphate de type IIc",
"description": "Quels sont les principaux facteurs de risque pour les troubles des cotransporteurs ?\nL'âge influence-t-il le risque de troubles ?\nLes maladies métaboliques sont-elles un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes médicaments peuvent-ils affecter le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050615#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des cotransporteurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de phosphate et de calcium peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les cotransporteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse d'urine et les tests génétiques peuvent être utilisés pour évaluer leur fonction."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de cotransporteurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la faiblesse musculaire ou des douleurs osseuses peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme les radiographies peuvent montrer des anomalies osseuses."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à identifier des maladies héréditaires ou des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en phosphate ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et douleurs osseuses."
}
},
{
"@type": "Question",
"name": "Comment se manifeste un excès de phosphate ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un excès peut entraîner des démangeaisons cutanées et des calcifications tissulaires."
}
},
{
"@type": "Question",
"name": "Les troubles osseux sont-ils liés aux cotransporteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles osseux comme l'ostéomalacie peuvent être liés à leur dysfonction."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés aux cotransporteurs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des fractures fréquentes et des douleurs articulaires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier, les enfants peuvent présenter des retards de croissance."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés aux cotransporteurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et des contrôles médicaux réguliers peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles métaboliques peuvent nécessiter une surveillance accrue."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur la santé des cotransporteurs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé osseuse et métabolique."
}
},
{
"@type": "Question",
"name": "Des suppléments préventifs sont-ils recommandés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments de phosphate peuvent être recommandés pour les personnes à risque."
}
},
{
"@type": "Question",
"name": "Comment l'hydratation influence-t-elle la santé des cotransporteurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hydratation est essentielle pour le bon fonctionnement des reins et des cotransporteurs."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles des cotransporteurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des suppléments de phosphate et des médicaments pour réguler les niveaux."
}
},
{
"@type": "Question",
"name": "La diététique joue-t-elle un rôle dans le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en phosphate peut aider à corriger les carences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents pour les enfants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être ajustés en fonction de l'âge et des besoins spécifiques."
}
},
{
"@type": "Question",
"name": "Des thérapies alternatives sont-elles efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent aider, mais doivent être discutées avec un médecin."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests réguliers des niveaux de phosphate et de calcium sont nécessaires pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction des cotransporteurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'ostéoporose et des troubles rénaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en provoquant des douleurs et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles plus fréquentes chez certains groupes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées et celles avec des antécédents familiaux sont plus à risque."
}
},
{
"@type": "Question",
"name": "Quelles mesures peuvent réduire les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement précoce peuvent réduire les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les troubles des cotransporteurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les maladies rénales et une alimentation déséquilibrée sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Les maladies métaboliques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète peuvent augmenter le risque de dysfonction des cotransporteurs."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec la fonction des cotransporteurs et augmenter le risque."
}
}
]
}
]
}
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. segawa@tokushima-u.ac.jp.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. kmiyamoto@tokushima-u.ac.jp.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Publications dans "Cotransporteurs sodium-phosphate de type IIc" :
Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated associations with positive kidney-related and cardiovascular outcomes in patients with type 2 diabetes. However, the associ...
To examine the long-term associations of SGLT-2is with mortality, major adverse kidney events (MAKEs), and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes and AKD....
This cohort study used global health care data (the TriNetX database) spanning from September 30, 2002, to September 30, 2022. Propensity score matching was used to select a cohort of patients, and fo...
The use of SGLT-2is....
The primary outcomes measured were mortality, MAKEs, and MACEs. Adjusted hazard ratios (AHR) with 95% CIs were calculated to compare the risks between SGLT-2i users and nonusers, representing the mean...
A total of 230 366 patients with AKD (mean [SD] age, 67.1 [16.4] years; 51.8% men and 48.2% women) were enrolled in the study, which had a median follow-up duration of 2.3 (IQR, 1.2-3.5) years. Among ...
In this cohort study of patients with type 2 diabetes and AKD, administration of SGLT-2is was associated with a significant reduction in all-cause mortality, MAKEs, and MACEs when compared with nonuse...
Serum phosphate levels remain insufficiently controlled in chronic kidney disease (CKD) patients, and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodi...
The in vitro cellular potency of DZ1462 was evaluated using a radioactive Pi uptake assay on stable Chinese hamster ovary (CHO) cell clones transfected with human NPT2b (hNPT2b) or rat NPT2b (rNPT2b)....
The cellular assays with the hNPT2b-CHO and rNPT2b-CHO clones showed that DZ1462 significantly and potently inhibited phosphate uptake. In vivo, in a chronic Pi-fed rat model, DZ1462 effectively inhib...
This study revealed that a GI-restricted NPT2b inhibitor DZ1462 potently inhibits NPT2b in vitro and blocks intestinal phosphate uptake in multiple animal models with potential to reduce various cardi...
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on calcium phosphate homeostasis in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remain uncertain....
A retrospective observational cohort study of patients with T2DM at CKD stage G3b-5ND who received SGLT2i as compared to control from 1 January 2015 through 31 December 2021 was recruited. Propensity ...
We analyzed 1,450 SGLT2i users and 4,350 control subjects. At the 12th month, SGLT2i users had a slower increase in phosphate levels (absolute change: -0.01 ± 0.28 vs + 0.14 ± 0.34 mmol/L; percentage ...
SGLT2i can effectively slow down the progression of phosphate retention in advanced CKD with T2DM....
Mitochondrial volume is maintained through the permeability of the inner mitochondrial membrane by a specific aquaporin and the osmotic balance between the mitochondrial matrix and cellular cytoplasm....
Gout is the most common form of inflammatory arthritis worldwide and is characterized by painful recurrent flares of inflammatory arthritis that are associated with a transiently increased risk of adv...
Diabetic nephropathy and diabetic retinopathy share many similarities in pathophysiological processes. Preclinical studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2is) have a pr...
To compare the risk of sight-threatening retinopathy associated with SGLT2is and other second-line glucose-lowering medications (including pioglitazone, sulfonylureas, and dipeptidyl peptidase-4 inhib...
This cohort study in Taiwan applied a new-user and active-comparator design. Patient demographic and clinical data were obtained from the National Health Insurance Research Database. Adult patients wi...
Treatment with SGLT2i, DPP-4i, pioglitazone, and sulfonylureas starting on January 1, 2016....
The main outcome was sight-threatening retinopathy in participants. Cox proportional hazards regression models were used to assess relative hazards of sight-threatening retinopathy between the matched...
A total of 3 544 383 patients with newly diagnosed T2D were identified. After 1:1 propensity score matching, 65 930 pairs of patients treated with SGLT2i vs DPP-4i, 93 760 pairs treated with SGLT2i vs...
This cohort study found that SGLT2i was associated with a lower risk of sight-threatening retinopathy compared with DPP-4i, pioglitazone, and sulfonylureas. This finding suggests that SGLT2i may play ...
Type 2 diabetes (T2D) is associated with an increased risk of kidney stones. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) might lower the risk of nephrolithiasis by altering urine composition. ...
To investigate the association between SGLT2i use and nephrolithiasis risk in clinical practice....
This new-user, active comparator cohort study used data from commercially insured adults (aged ≥18 years) with T2D who initiated treatment with SGLT2is, glucagon-like peptide 1 receptor agonists (GLP-...
New initiation of an SGLT2i, GLP-1RA, or DPP4i....
The primary outcome was nephrolithiasis diagnosed by International Classification of Diseases codes in the inpatient or outpatient setting. New SGLT2i users were 1:1 propensity score matched to new us...
After 1:1 propensity score matching, a total of 716 406 adults with T2D (358 203 pairs) initiating an SGLT2i or a GLP-1RA (mean [SD] age, 61.4 [9.7] years for both groups; 51.4% vs 51.2% female; 48.6%...
These findings suggest that in adults with T2D, SGLT2i use may lower the risk of nephrolithiasis compared with GLP-1RAs or DPP4is and could help to inform decision-making when prescribing glucose-lowe...
Sodium-glucose cotransporter-2 inhibitors have been shown to have significant metabolic, renal, and atherosclerotic cardiovascular disease benefits. Recent randomized controlled trials have extended t...
Obesity is becoming increasingly prevalent in China and worldwide and is closely related to the development of hypertension. The pathophysiology of obesity-associated hypertension is complex, includin...
We sought to determine whether the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assemb...